VIRTUAL DREAM: Pilot Study on the Evaluation of the Effectiveness of a Virtual Reality Device on Anxiety During Procedural Sedation in Traumatology in Emergency Department

Sponsor
Poitiers University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04936880
Collaborator
(none)
60
1
2
17
3.5

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate the efficiency of a reality device and a virtual hypnosis software to reduce the anxiety during reduction procedure in traumatology in an emergency department. These devices have recently been evaluated in the management of pain and anxiety in different specialties but never in the context of analgesia-sedation protocols in emergencies.

Condition or Disease Intervention/Treatment Phase
  • Device: Experimental : Virtual reality + analgesia-sedation
  • Drug: Control: Analgesia-sedation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Pilot Study on the Evaluation of the Effectiveness of a Virtual Reality Device on Anxiety During Procedural Sedation in Traumatology in Emergency Department
Actual Study Start Date :
Jul 1, 2021
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental : Virtual reality + analgesia-sedation

Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure

Device: Experimental : Virtual reality + analgesia-sedation
Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure

Active Comparator: Control: Analgesia-sedation

Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure

Drug: Control: Analgesia-sedation
Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure

Outcome Measures

Primary Outcome Measures

  1. Difference in anxiety level [30 minutes]

    Difference in anxiety level measured with a visual analog scale between T1 (before the analgesia-sedation procedure) and T4 (30 minutes after the procedure was performed, by asking the patient to rate the anxiety he or she felt during the procedure) during a technical procedure in traumatology in the emergency department in the VR group compared with the control group. The level of anxiety is measured with a visual analog scale (0: no anxiety, 10: maximum anxiety).

Secondary Outcome Measures

  1. Difference in pain intensity [30 minutes]

    The level of pain is measured with a visual analog scale (0: no pain, 10: maximum pain).

  2. Doses of analgesics [During the procedure]

    Total doses of analgesics used during a technical procedure performed in the context of trauma in the experimental group compared with the control group.

  3. Occurrence of headache, nausea/vomiting, dizziness or confusional episode [During the procedure]

    Tolerance assessed by looking for the occurrence of headache, nausea/vomiting, dizziness or confusional episode in both groups.

  4. Evaluation of satisfaction [30 minutes]

    Comparison of the patient's level of satisfaction with pain and anxiety management between the two groups, assessed using a numerical scale ranging from 0 (not satisfied) to 10 (totally satisfied).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient aged 18 years or older

  • Patient suffering from one of the following traumatic pathologies requiring a technical procedure in the emergency room Shoulder dislocation Ankle dislocation Elbow dislocation Wrist dislocation Reducible fractures

  • No contraindication to Virtual Reality

  • No contraindication to morphine, ketamine, propofol, paracetamol, nefopam and MEOPA

  • Patient having given oral, free and informed consent

Exclusion Criteria:
  • Patients suffering from mono or binocular blindness

  • Patient under the influence of alcohol or psychotropic drugs

  • Patient presenting a psychosis and/or a state of agitation, and/or a state of confusion.

  • Patient presenting a hemodynamic, respiratory or neurological failure

  • Patient with at least one of the following symptoms at the time of inclusion in the study: headache, dizziness, nausea, vomiting

  • Persons benefiting from reinforced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection (guardianship and trusteeship) and finally patients in a vital emergency situation.

  • Pregnant or breastfeeding women, women of childbearing age who do not have effective contraception (hormonal/mechanical: per os, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy)

  • Concurrent participation in another clinical research study whose objective is the evaluation of anxiety and/or pain

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital of Poitiers Poitiers France 86021

Sponsors and Collaborators

  • Poitiers University Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Poitiers University Hospital
ClinicalTrials.gov Identifier:
NCT04936880
Other Study ID Numbers:
  • VIRTUAL DREAM
First Posted:
Jun 23, 2021
Last Update Posted:
Aug 19, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 19, 2022